Aleniglipron
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Gasherbrum Bio, Inc · Phase 1 · Status n/r · Enrollment 70
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet | n/r | n/r | n/r | n/r | n/r |
| Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule | n/r | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 1): GSBR-1290/Placebo Tablet | n/r | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 2): GSBR-1290/Placebo Tablet | n/r | n/r | n/r | n/r | n/r |
| Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.